Concepts (81)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glutamates | 2 | 2011 | 90 | 0.440 |
Why?
|
| Antineoplastic Agents | 4 | 2018 | 2385 | 0.430 |
Why?
|
| Guanine | 2 | 2011 | 207 | 0.420 |
Why?
|
| Cortactin | 1 | 2011 | 11 | 0.360 |
Why?
|
| Quantitative Trait Loci | 2 | 2011 | 632 | 0.330 |
Why?
|
| Pemetrexed | 3 | 2018 | 76 | 0.310 |
Why?
|
| MicroRNAs | 4 | 2018 | 591 | 0.290 |
Why?
|
| Carrier Proteins | 1 | 2011 | 681 | 0.280 |
Why?
|
| Nuclear Proteins | 1 | 2011 | 750 | 0.260 |
Why?
|
| Apoptosis | 1 | 2011 | 1756 | 0.220 |
Why?
|
| Watchful Waiting | 1 | 2024 | 71 | 0.210 |
Why?
|
| Urologic Neoplasms | 1 | 2024 | 78 | 0.200 |
Why?
|
| Lymphocytes | 2 | 2018 | 465 | 0.190 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2024 | 156 | 0.190 |
Why?
|
| Neoplasm Invasiveness | 1 | 2024 | 579 | 0.190 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2024 | 224 | 0.180 |
Why?
|
| Cell Line, Tumor | 5 | 2018 | 2777 | 0.170 |
Why?
|
| Carboplatin | 2 | 2012 | 328 | 0.160 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2024 | 382 | 0.160 |
Why?
|
| Cisplatin | 2 | 2012 | 599 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2013 | 644 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 1021 | 0.140 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2012 | 2495 | 0.110 |
Why?
|
| Genome-Wide Association Study | 3 | 2011 | 1766 | 0.110 |
Why?
|
| Interleukin-11 | 1 | 2013 | 20 | 0.100 |
Why?
|
| Floxuridine | 1 | 2011 | 10 | 0.090 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2011 | 21 | 0.090 |
Why?
|
| Microfilament Proteins | 1 | 2013 | 213 | 0.090 |
Why?
|
| Twins, Monozygotic | 1 | 2011 | 58 | 0.090 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2013 | 303 | 0.090 |
Why?
|
| Caspases | 1 | 2011 | 156 | 0.090 |
Why?
|
| Gene Expression | 2 | 2012 | 1319 | 0.080 |
Why?
|
| Cytarabine | 1 | 2011 | 218 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2018 | 1192 | 0.080 |
Why?
|
| Linear Models | 1 | 2011 | 438 | 0.080 |
Why?
|
| Paclitaxel | 1 | 2011 | 488 | 0.080 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 2061 | 0.070 |
Why?
|
| RNA-Binding Proteins | 1 | 2011 | 305 | 0.070 |
Why?
|
| Pharmacogenetics | 1 | 2011 | 456 | 0.070 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 2386 | 0.060 |
Why?
|
| Phenotype | 1 | 2011 | 2575 | 0.050 |
Why?
|
| Intention to Treat Analysis | 1 | 2024 | 81 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2011 | 1422 | 0.050 |
Why?
|
| Gene Expression Profiling | 3 | 2018 | 1535 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2024 | 517 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2024 | 306 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2024 | 883 | 0.050 |
Why?
|
| HapMap Project | 2 | 2012 | 47 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2024 | 1194 | 0.040 |
Why?
|
| Humans | 7 | 2024 | 95799 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2024 | 2042 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 3155 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2018 | 234 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2013 | 1346 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2018 | 705 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2024 | 7215 | 0.030 |
Why?
|
| Suppression, Genetic | 1 | 2013 | 30 | 0.020 |
Why?
|
| GATA3 Transcription Factor | 1 | 2013 | 52 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2012 | 64 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2013 | 106 | 0.020 |
Why?
|
| Young Adult | 1 | 2024 | 7026 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2013 | 290 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 299 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2013 | 393 | 0.020 |
Why?
|
| Cytoskeleton | 1 | 2013 | 200 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 528 | 0.020 |
Why?
|
| Models, Biological | 1 | 2018 | 1809 | 0.020 |
Why?
|
| Cell Survival | 1 | 2013 | 1029 | 0.020 |
Why?
|
| Haplotypes | 1 | 2012 | 650 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2011 | 703 | 0.020 |
Why?
|
| Cell Line | 1 | 2011 | 2536 | 0.020 |
Why?
|
| Aged | 1 | 2024 | 20848 | 0.020 |
Why?
|
| Female | 2 | 2024 | 49869 | 0.010 |
Why?
|
| Transcriptome | 1 | 2011 | 770 | 0.010 |
Why?
|
| Prognosis | 1 | 2013 | 3990 | 0.010 |
Why?
|
| Middle Aged | 1 | 2024 | 28206 | 0.010 |
Why?
|
| Adult | 1 | 2024 | 28578 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 1670 | 0.010 |
Why?
|
| Male | 1 | 2024 | 45685 | 0.010 |
Why?
|
| Mice | 1 | 2013 | 12537 | 0.010 |
Why?
|
| Animals | 1 | 2013 | 28889 | 0.010 |
Why?
|